TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8878350

Group type: EXPERIMENTAL
Intervention: Pentagastrin (0.6 micrograms/kg IV)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Pentagastrin
Number of subjects: 14
Study: 1281648

Group type: EXPERIMENTAL
Intervention: ER-PAR in patients with advanced breast cancer
Number of subjects: 619

Group type: COMPARATOR
Intervention: Tamoxifen treatment in receptor-defined subgroups
Number of subjects: 619

Group type: COMPARATOR
Intervention: ER-DCC and ER-PAR comparison
Number of subjects: 619

Group type: COMPARATOR
Intervention: ER-ICA and ER-DCC correlation
Number of subjects: 619

Group type: COMPARATOR
Intervention: ER-PAR prognostic value
Number of subjects: 619
Study: 31710345

Group type: EXPERIMENTAL
Intervention: PACE Steps to Success Program
Number of subjects: 551

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 551
Study: 30993423

Group type: EXPERIMENTAL
Intervention: High cumulative dose of DMF exposure
Number of subjects: 672

Group type: EXPERIMENTAL
Intervention: GOT2 gene polymorphism (rs7204324)
Number of subjects: 672

Group type: COMPARATOR
Intervention: CYP2E1 gene polymorphisms (rs2031920, rs3813867, rs6413432)
Number of subjects: 672
Study: 26471495

Group type: EXPERIMENTAL
Intervention: GDFT (Goal Directed Fluid Therapy)
Number of subjects: 120

Group type: COMPARATOR
Intervention: CONTROL (no-protocol treatment)
Number of subjects: 120
Study: 23413771

Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 0
Study: 21220060

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 215
Study: 19552020

Group type: EXPERIMENTAL
Intervention: Multisubstrate nutritional cocktail (0.3 g/kg protein weight, 7.5 g fibers per day, 10 kcal/kg body weight) in addition to conventional treatment.
Number of subjects: 61

Group type: COMPARATOR
Intervention: Conventional treatment (lactulose, beta-blocker, spironolactone based on 1.2 g/kg protein weight and 30 kcal/kg body weight per day).
Number of subjects: 61
Study: 18572750

Group type: EXPERIMENTAL
Intervention: saquinavir/ritonavir 1,600/100 mg per day plus two NRTIs
Number of subjects: 272
Study: 15762881

Group type: EXPERIMENTAL
Intervention: Mycobacterium vaccae
Number of subjects: 12
Study: 12092000

Group type: EXPERIMENTAL
Intervention: Fibrin glue (Quixil) - 0.3 ml sprayed to each bleeding nostril
Number of subjects: 204

Group type: COMPARATOR
Intervention: Electric cautery
Number of subjects: 204

Group type: COMPARATOR
Intervention: Silver nitrate coagulation
Number of subjects: 204

Group type: COMPARATOR
Intervention: Foam nasal packing
Number of subjects: 204
Study: 10363623

Group type: EXPERIMENTAL
Intervention: 0.3% netilmicin ophthalmic solution
Number of subjects: 45

Group type: COMPARATOR
Intervention: 0.3% tobramycin
Number of subjects: 45
Study: 7491392

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine (0.25 mg/kg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 1664978

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (daily injection)
Number of subjects: 204

Group type: COMPARATOR
Intervention: No prophylaxis (control group)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (in patients with fractures)
Number of subjects: 204

Group type: COMPARATOR
Intervention: No prophylaxis (control group in patients with fractures)
Number of subjects: 204
Study: 7071793

Group type: EXPERIMENTAL
Intervention: Suction drainage (up to 20 cm H2O pressure)
Number of subjects: 53

Group type: COMPARATOR
Intervention: No suction drainage
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Early catheter removal (as soon as the lung was expanded)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Late catheter removal (catheters left in situ for a further three days)
Number of subjects: 53
Study: 31229205

Group type: EXPERIMENTAL
Intervention: Classical massage (CMG) before each paclitaxel infusion
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Classical massage (CMG)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (CG) receiving usual care
Number of subjects: 40
Study: 28608394

Group type: EXPERIMENTAL
Intervention: Beer
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Nonalcoholic beer (na-beer)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Gin
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Beer and nonalcoholic beer (na-beer)
Number of subjects: 33
Study: 26494562

Group type: EXPERIMENTAL
Intervention: Multi-level intervention including a primary care electronic CKD registry and a language-concordant self-management support program.
Number of subjects: 0
Study: 23524688

Group type: EXPERIMENTAL
Intervention: Hydrogel with BMP-2 (250 µg/mL)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hydrogel alone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Tisseel with autograft
Number of subjects: 12

Group type: COMPARATOR
Intervention: Spongostan (negative control)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Tisseel mixed with bone autograft (control group)
Number of subjects: 12
Study: 21509444

Group type: EXPERIMENTAL
Intervention: Intensive glucose control
Number of subjects: 11140

Group type: COMPARATOR
Intervention: Standard glucose control
Number of subjects: 11140
Study: 19452730

Group type: EXPERIMENTAL
Intervention: Tonsillectomy and adenoidectomy
Number of subjects: 61

Group type: COMPARATOR
Intervention: Tonsillar and adenoidal hypertrophy (compared to control children)
Number of subjects: 61
Study: 17869307

Group type: EXPERIMENTAL
Intervention: Tookad vascular targeted photodynamic therapy (0.1 to 2 mg/kg) with a fixed light dose of 100 J/cm
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Tookad vascular targeted photodynamic therapy (2 mg/kg) with escalated light doses of 230 and 360 J/cm
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Tookad vascular targeted photodynamic therapy
Number of subjects: 6
Study: 15650343

Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg plus statin (lovastatin, pravastatin, simvastatin, atorvastatin)
Number of subjects: 1861

Group type: COMPARATOR
Intervention: Statin monotherapy (lovastatin or pravastatin 10, 20, or 40 mg; simvastatin or atorvastatin 10, 20, 40, or 80 mg)
Number of subjects: 1861
Study: 11589675

Group type: EXPERIMENTAL
Intervention: DHEA 50 mg per day for 4 months (n = 14)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (n = 18)
Number of subjects: 32
Study: 9626926

Group type: EXPERIMENTAL
Intervention: Tegretol (branded carbamazepine)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CBZ Pharmachemie (generic carbamazepine)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CBZ Pharbita (generic carbamazepine)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 12
Study: 7884977

Group type: EXPERIMENTAL
Intervention: Memory group (n=25)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Impression group (n=24)
Number of subjects: 49
Study: 3126350

Group type: EXPERIMENTAL
Intervention: recombinant tissue‐type plasminogen activator (rt‐PA) 80 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: streptokinase (SK) 1.5 million units
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: old rt‐PA 80 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: new rt‐PA 80 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: new rt‐PA 100 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: new rt‐PA 150 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: new rt‐PA (various doses)
Number of subjects: 100
Study: 29128787

Group type: EXPERIMENTAL
Intervention: Direct and indirect handwashing interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-intervention control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 0
Study: 26679894

Group type: EXPERIMENTAL
Intervention: Pilates
Number of subjects: 510

Group type: COMPARATOR
Intervention: Minimal intervention
Number of subjects: 510
Study: 25622920

Group type: COMPARATOR
Intervention: Static Stretching (SS)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Contract-Relax Stretching (CRS)
Number of subjects: 20
Study: 23073817

Group type: EXPERIMENTAL
Intervention: Vertical incision
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Transverse incision
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Oblique incision
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (Transverse and Oblique)
Number of subjects: 120
Study: 20386144

Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL) with rabbit antithymocyte globulin induction
Number of subjects: 141

Group type: COMPARATOR
Intervention: Tacrolimus
Number of subjects: 141
Study: 17655971

Group type: EXPERIMENTAL
Intervention: Mixing grapefruit juice with sucrose
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Mixing broccoli or cauliflower with sugar
Number of subjects: 111
Study: 15737106

Group type: EXPERIMENTAL
Intervention: risperidone
Number of subjects: 5

Group type: COMPARATOR
Intervention: conventional antipsychotic agents
Number of subjects: 5
Study: 11972144

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) with high frequencies (above 5 Hz) applied to the left dorsolateral prefrontal cortex
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) with low frequencies applied to the right dorsolateral prefrontal cortex
Number of subjects: 0
Study: 10599054

Group type: EXPERIMENTAL
Intervention: Cholinesterase inhibitor metrifonate (MTF) treatment for 6 months
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cholinesterase inhibitor metrifonate (MTF) treatment for 2 years or more
Number of subjects: 12

Group type: COMPARATOR
Intervention: No treatment (off MTF)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cholinesterase inhibitor metrifonate (MTF) treatment
Number of subjects: 12
Study: 7487242

Group type: EXPERIMENTAL
Intervention: Educational brochure and encouragement to execute durable health care proxies
Number of subjects: 162

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 162
Study: 1773579

Group type: EXPERIMENTAL
Intervention: Nomogram for dosing warfarin
Number of subjects: 65

Group type: COMPARATOR
Intervention: Computer program for dosing warfarin
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Measured PTR
Number of subjects: 65
Study: 7053286

Group type: EXPERIMENTAL
Intervention: Antihypertensive drugs prescribed to 63% of patients
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: More vigorous treatments prescribed
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Patient compliance with treatment
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Product of prescribed vigor and compliance
Number of subjects: 230
Study: 31955271

Group type: EXPERIMENTAL
Intervention: Zirconia crowns
Number of subjects: 30

Group type: COMPARATOR
Intervention: Stainless steel crowns
Number of subjects: 30
Study: 29110574

Group type: EXPERIMENTAL
Intervention: Medical Therapy (MT)
Number of subjects: 307

Group type: COMPARATOR
Intervention: Surgical Treatment (ST)
Number of subjects: 307
Study: 25533021

Group type: EXPERIMENTAL
Intervention: Combined individual dietary counseling with individualized swallowing therapy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Individual dietary counseling
Number of subjects: 120
Study: 24832727

Group type: EXPERIMENTAL
Intervention: Dietary grape powder
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo powder
Number of subjects: 24
Study: 23972414

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for relatively active patients
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for passive patients
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 60
Study: 20569761

Group type: EXPERIMENTAL
Intervention: STAFF
Number of subjects: 9835

Group type: EXPERIMENTAL
Intervention: AUTO
Number of subjects: 9835

Group type: COMPARATOR
Intervention: NONE
Number of subjects: 9835
Study: 18761065

Group type: EXPERIMENTAL
Intervention: Riboflavin-5'-phosphate sodium salt (RF5P) delivered via gastro-mucoadhesive delivery system based on ion-exchange fiber; specific dosage and duration not mentioned.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modified dissolution system (flow through diffusion cell) used to study drug release; specific details not mentioned.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gastrointestinal transit studies in rats; specific details not mentioned.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gamma imaging study in human volunteers; specific details not mentioned.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Analysis of urinary excretion of riboflavin in humans; specific details not mentioned.
Number of subjects: 0
Study: 16822237

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (4 g/day)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Olive oil supplementation (4 g/day)
Number of subjects: 83
Study: 12814446

Group type: EXPERIMENTAL
Intervention: 08.00 h dosing of 3 micro g oral vitamin D3
Number of subjects: 13

Group type: COMPARATOR
Intervention: 20.00 h dosing of 3 micro g oral vitamin D3
Number of subjects: 13
Study: 10888694

Group type: EXPERIMENTAL
Intervention: Interactive educational computer program, Asthma Control
Number of subjects: 137

Group type: COMPARATOR
Intervention: Printed educational materials with a research assistant
Number of subjects: 137
Study: 8740611

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Active drugs
Number of subjects: 525
Study: 8241702

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (100 mg per day) given orally for 14 days before and 30 days after surgery
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (100 mg per day)
Number of subjects: 10
Study: 2859412

Group type: EXPERIMENTAL
Intervention: HB immunoglobulin and 2 doses of HB vaccine 2 months apart
Number of subjects: 214

Group type: COMPARATOR
Intervention: HB immunoglobulin and 3 doses of HB vaccine 1 month apart
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: 2 doses of vaccine 2 months apart
Number of subjects: 214

Group type: COMPARATOR
Intervention: 3 doses of vaccine 1 month apart
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: 2-dose regimen
Number of subjects: 214

Group type: COMPARATOR
Intervention: 3-dose regimen
Number of subjects: 214
Study: 30982467

Group type: EXPERIMENTAL
Intervention: Adaptive Cogmed training
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-adaptive Cogmed training (control)
Number of subjects: 100
Study: 29400641

Group type: COMPARATOR
Intervention: Normal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alzheimer's disease (AD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Wernicke‐Korsakoff Syndrome (WKS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chronic traumatic encephalopathy (CTE)
Number of subjects: 0
Study: 26524984

Group type: EXPERIMENTAL
Intervention: Narrowband ultraviolet B (NB‐UVB) exposures, 2 standard erythema doses (SEDs) every second week from October 2013 to April 2014
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (no NB‐UVB exposure)
Number of subjects: 34
Study: 24485082

Group type: EXPERIMENTAL
Intervention: Bipolar TURP
Number of subjects: 60

Group type: COMPARATOR
Intervention: Monopolar TURP
Number of subjects: 60
Study: 22878869

Group type: COMPARATOR
Intervention: Tropisetron (0.1 mg/kg; maximal dose, 5 mg)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Tropisetron (0.1 mg/kg; maximal dose, 5 mg) plus Penehyclidine (0.01 mg/kg; maximal dose, 1 mg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Penehyclidine (0.01 mg/kg; maximal dose, 1 mg)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Tropisetron plus Penehyclidine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Tropisetron
Number of subjects: 120

Group type: COMPARATOR
Intervention: Penehyclidine
Number of subjects: 120
Study: 20876698

Group type: EXPERIMENTAL
Intervention: Sevoflurane with high effect-site concentration of remifentanil (SH)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Sevoflurane with low effect-site concentration of remifentanil (SL)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Propofol with high effect-site concentration of remifentanil (PH)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Propofol with low effect-site concentration of remifentanil (PL)
Number of subjects: 214
Study: 18947293

Group type: EXPERIMENTAL
Intervention: AdheSE One (new premixed self-etching adhesive)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Transbond Plus (self-etching primer)
Number of subjects: 40
Study: 15867284

Group type: EXPERIMENTAL
Intervention: Low-fat, high-fiber diet with 25 g/d soy protein (+ 90 mg/d isoflavones)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Low-fat, high-fiber diet with 25 g/d milk protein
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Low CRP group (regardless of protein source)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: High CRP group (regardless of protein source)
Number of subjects: 32
Study: 12975413

Group type: EXPERIMENTAL
Intervention: Beta MHC gene mutation
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 70
Study: 11593526

Group type: EXPERIMENTAL
Intervention: Captopril 25 to 50 mg bid for 12 weeks
Number of subjects: 278
Study: 9038448

Group type: EXPERIMENTAL
Intervention: Non-invasive technique using a neonatal oscillometric blood pressure monitor attached to the thumb
Number of subjects: 18

Group type: COMPARATOR
Intervention: Invasive technique using a catheter inserted into the ipsilateral radial artery
Number of subjects: 18
Study: 1531286

Group type: EXPERIMENTAL
Intervention: Midazolam (0.2 mg/kg)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Sufentanil (2 micrograms/kg)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Sufentanil
Number of subjects: 95
Study: 3934964

Group type: EXPERIMENTAL
Intervention: Antihyperglycemic therapy
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: 250 mg per day of sorbinil
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 31142290

Group type: EXPERIMENTAL
Intervention: Supervised training including aerobic and resistance exercises of moderate/high intensity
Number of subjects: 540

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 540
Study: 28843487

Group type: EXPERIMENTAL
Intervention: Nilotinib 400 mg orally twice daily
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Nilotinib
Number of subjects: 25
Study: 25911523

Group type: EXPERIMENTAL
Intervention: Remote therapy from University lab
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Remote therapy from clinical site
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Face to face therapy
Number of subjects: 21

Group type: COMPARATOR
Intervention: Attention control (remotely delivered supported conversation)
Number of subjects: 21
Study: 24407777

Group type: EXPERIMENTAL
Intervention: Symptom-triggered regimen of lorazepam
Number of subjects: 63

Group type: COMPARATOR
Intervention: Fixed tapering dose regimen of lorazepam
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 63
Study: 20478467

Group type: EXPERIMENTAL
Intervention: 5.25% NaOCl for 10 minutes
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 3% H2O2 for 10 minutes
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 17% EDTA for 10 minutes
Number of subjects: 20

Group type: COMPARATOR
Intervention: Distilled water (control)
Number of subjects: 20
Study: 15944868

Group type: EXPERIMENTAL
Intervention: Estrogen patch for 36 hours
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo patch for 36 hours
Number of subjects: 19
Study: 12218734

Group type: EXPERIMENTAL
Intervention: Physical Training (PT) for 4 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no specific intervention mentioned)
Number of subjects: 0
Study: 9498887

Group type: EXPERIMENTAL
Intervention: 3.75 mg midazolam
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 7.5 mg midazolam
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 11.25 mg midazolam
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 15 mg midazolam
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 8147070

Group type: EXPERIMENTAL
Intervention: Diltiazem (D) - 300 micrograms/kg bolus and 5.4 micrograms/kg/min continuous infusion
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nisoldipine (N) - 5 micrograms/kg bolus and 0.2 micrograms/kg/min continuous infusion
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 20
Study: 3168559

Group type: EXPERIMENTAL
Intervention: Peroral intestinal cleansing with 1.5 l cold electrolyte solution
Number of subjects: 55

Group type: COMPARATOR
Intervention: Rectal lavaging
Number of subjects: 55
Study: 11903525

Group type: EXPERIMENTAL
Intervention: Intravenous valproate 500 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intramuscular dihydroergotamine 1 mg with metoclopramide 10 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intravenous valproate
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intramuscular dihydroergotamine
Number of subjects: 40
Study: 30488954

Group type: EXPERIMENTAL
Intervention: Video modelling intervention (brief video model created by a dentist)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control video
Number of subjects: 40
Study: 29443825

Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine (IIV)
Number of subjects: 10002

Group type: COMPARATOR
Intervention: Control (saline placebo or quadrivalent meningococcal conjugate vaccine)
Number of subjects: 10002
Study: 27267860

Group type: EXPERIMENTAL
Intervention: Right LLLT (transcranial laser stimulation)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Left LLLT (transcranial laser stimulation)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Sham LLLT (control group)
Number of subjects: 51
Study: 25064429

Group type: EXPERIMENTAL
Intervention: Bilateral sagittal split osteotomy set-back of the mandible (BSSO)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Le Fort I advancement of the maxilla
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Combination of both BSSO and Le Fort I
Number of subjects: 83